Menu
IBM puts Watson to work on cancer with new patient-advisor tool

IBM puts Watson to work on cancer with new patient-advisor tool

It will tap natural language processing and offer personalised advice

IBM's Watson West hub in San Francisco. Credit: Tony Avelar/IBM

IBM's Watson West hub in San Francisco. Credit: Tony Avelar/IBM

IBM is developing a new weapon in the battle against cancer that will put Watson to work in a new way. Partnering with the American Cancer Society, IBM is building a virtual advisor that uses machine learning to give patients personalised information and advice.

The advisor will begin by looking at the type of cancer the patient is suffering from, the stage of the disease and the treatments administered so far. Using that and other data, it will try to offer care advice and answer patients' questions.

Watson's voice recognition and natural language processing will enable users to ask questions and receive audible responses.

A person with breast cancer, for instance, could ask the advisor what might be causing her pain. Having learned from the experiences of people with similar characteristics, the tool can respond with information about symptoms and options for self care based on the patient's situation.

Over time, the advisor will become increasingly personalised as it learns more about the user, resulting in recommendations that match her preferences, such as for online support groups over telephone calls.

To create the tool, IBM and ACS will tap their massive combined stores of data and use it to train Watson. Included in that data will be Cancer.org's 14,000 pages of detailed information on more than 70 cancer topics as well as the ACS National Cancer Information Center’s aggregated data about self-management, support groups, wellness activities and cancer education.

The tool will also surface insights from IBM's Watson Health Cloud.

"It’s about providing the right information to the right people at the right time,” said Gary Reedy, CEO of the American Cancer Society.

More than 1.6 million Americans are diagnosed with cancer each year. IBM's effort is one of several in the tech industry that aim to make it easier to share and analyse large amounts of data to help treat patients and, ultimately, advance cures for diseases. Intel has a project called the Collaborative Cancer Cloud, for instance, which will allow hospitals and universities to more easily share genomic, imaging and clinical patient data for research purposes.

Ultimately, ACS and IBM aim to integrate their patient advisor with IBM’s existing Watson for Oncology offering for doctors.

In related news, IBM on Tuesday also launched a new program called the IBM Health Corps that aims to help communities address health challenges around the world.

Follow Us

Join the New Zealand Reseller News newsletter!

Error: Please check your email address.

Tags virtual advisorAmerican Cancer SocietyIBMWatsoncancer research

Slideshows

IN PICTURES: Ingram Micro Innovation hits Auckland with Hewlett Packard Enterprise

IN PICTURES: Ingram Micro Innovation hits Auckland with Hewlett Packard Enterprise

Ingram Micro completed its nationwide roadshow in Auckland last month, kicking off its Innovation Hour series with Hewlett Packard Enterprise. Uncovering the latest in storage, networking and servers, the event outlined key market trends for resellers in 2016 and beyond.

IN PICTURES: Ingram Micro Innovation hits Auckland with Hewlett Packard Enterprise
IN PICTURES: FireEye celebrates channel at 2016 Partner Conference

IN PICTURES: FireEye celebrates channel at 2016 Partner Conference

FireEye welcomed 143 channel partners and distributors to FireEye's 2016 annual Partner Conference, FireEye A/NZ Momentum - held at Establishment in Sydney. Delegates heard from senior trans-Tasman channel leaders, marketing and the product divisions in the morning, with FireEye customers, incident responders and threat intelligence analysts sharing knowledge during the afternoon.

IN PICTURES: FireEye celebrates channel at 2016 Partner Conference
Show Comments